IPSEN (OTCMKTS:IPSEY) Short Interest Update

IPSEN (OTCMKTS:IPSEY) was the target of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 268 shares, an increase of 87.4% from the June 15th total of 143 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 1,589 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

IPSEY has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold”.

IPSEN Price Performance

Shares of IPSEN stock remained flat at $44.07 during trading on Thursday. 383 shares of the company traded hands, compared to its average volume of 993. The business’s 50 day moving average price is $46.77 and its two-hundred day moving average price is $44.75. IPSEN has a 52 week low of $30.05 and a 52 week high of $51.10.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).